ESG

For the fifth year, GCM Grosvenor is a top workplace. We explore how their people-first strategy is a key asset in the competitive world of finance.

Sana Biotech’s new data shows it can edit stem cells directly in the body, a potential game-changer for blood disorders and a challenge to current therapies.

As AI-driven deepfakes surge, a 5-year-old film reveals why media literacy is the most critical, yet overlooked, infrastructure for our smart cities.

SS Innovations is betting its cost-efficient SSi Mantra robot can break into the U.S. market. Will affordability democratize the operating room?

John Crowley, who fought to save his own children, will now shape the future of medicine as he headlines the landmark 2026 MDA conference.

One junior miner in Québec is rewriting the script by owning its mill, a strategic move that de-risks the path from exploration to cash flow.

Vyome's positive Phase 2 data targets a silent suffering in cancer care. This analysis explores its strategy to dominate a potential $1 billion market.

SAB Biotherapeutics' novel T1D therapy shows promise with a unique safety profile, challenging the status quo and offering new hope for patients.

EyeYon Medical's synthetic corneal implant, EndoArt, just got FDA approval for U.S. trials, offering a fix for the global donor tissue shortage.

Newron launches a pivotal US trial for its novel schizophrenia drug, evenamide, aiming to help millions who don't respond to current treatments.

New data reveals Syndax's Revuforj is a game-changer for leukemia, sparking a battle for market dominance in targeted cancer therapy.

A breakthrough drug for a rare brain cancer sweeps prestigious international awards, offering patients a new, targeted therapy to delay aggressive treatments.

A breakthrough eco-friendly antioxidant, SA6000, could slash the environmental impact of tires. But can this molecular innovation scale for global impact?

A new $4.2 billion coastal city in Muscat aims to merge luxury living with a digital economy. Can Oman's 'MAD' project redefine real estate and its future?

AsymBio's massive Shanghai facility isn't just about capacity; it's a key move in the high-stakes world of advanced biologic drug production.

New 52-week data shows Protagonist and Takeda's drug slashes phlebotomy needs, signaling a major shift in quality of life for polycythemia vera patients.

A medical breakthrough dismantles a core barrier in cancer treatment, making stem cell transplants a reality for nearly everyone, regardless of ancestry.

A government crackdown on clergy and a top businessman raises serious questions about Armenia's judicial independence, spooking investors and allies alike.

Boston-based 1910 Genetics unveils an AI model that bypasses decades-old barriers, opening a vast new frontier for treating Alzheimer's and Parkinson's.

A utility is slashing its carbon footprint by 99.9% not with solar or wind, but with an invisible innovation that fixes the grid from the inside out.